Is the manufacturer a factory?

Yes, we are a manufacturer and trading company established in 2017.

What is the purity level of the reagent?

The product features high purity suitable for antigen-antibody reagents.

Good Quality Reagent Kit Raw Materials Cystatin C in Vitro Diagnosis

Name: Good Quality Reagent Kit Raw Materials Cystatin C in Vitro Diagnosis
Brand: Hubei New Desheng Material Technology Co., Ltd
SKU: 2059662895

Hubei, ChinaHubei New Desheng Material Technology Co., Ltd

US$212.00

10 gram

Product profile

Customization

Available

CAS No.

91448-99-6

Formula

13kda

Model NO.

CYSTATIN C

EINECS

Non

Appearance

Powder

Usage

Diagnostic Reagent

Color

White

OEM Packing

Yes

in Vitro Diagnosis

Yes

Antigen-Antibody Reagent

Yes

Purity

High

Transport Package

Bottle

Trademark

Desheng

Origin

China

HS Code

3006300000

Key features

Ideal GFR Marker: Cystatin C is a sensitive and specific endogenous substance for assessing renal function.

High Purity: Raw materials feature high purity suitable for diagnostic reagents.

OEM and ODM Services: Customization from samples available with OEM packing options.

Stable Performance: Professional manufacturer with wide range of products and high sensitivity.

White Powder Form: Appearance is white powder with CAS No. 91448-99-6.

15-Day Lead Time: Average lead time within 15 workdays for both peak and off-peak seasons.

Traceable Raw Materials: Full traceability of raw materials ensures quality and safety.

Multiple Payment Options: Accepts LC, T/T, PayPal, Western Union, and small-amount payments.

Company profile

Importers and ExportersPatents AwardedExhibition Experience

Hubei New Desheng Material Technology Co., Ltd

Hubei, China

CertifiedBusiness Type: Manufacturer/Factory & Trading Company CertifiedR&D Capacity: ODM Service Available & OEM Service Available CertifiedCustomization Options: Customization from Samples CertifiedExport Year: 7 Years CertifiedNearest Port: Shanghai PortAverage Response Time: ≤7.25h

AI-Powered supplier vetting

SummaryThe supplier is a combined manufacturing and trading enterprise with chemical, synthetic-material, medical-device, and related product activities. It reports two production lines, specified annual capacities for several products, finished-product inspection instructions, inventory capability, and an off-peak lead time within 15 working days. Service processes for corrective and preventive actions and customer complaints are documented and followed. R&D personnel provide technical support, with design and verification records available for audit, but no SDK is available. The supplier provides OEM services for well-known brands and can customize from samples. Limitations include no valid manufacturing-capacity contract with related subcontractors, no overseas warehouse, showroom, agent, or branch, and no stated overseas service countries. No explicit certification holdings or customer case details are provided.

Supplier typeThe supplier’s stated scope covers manufacturing of basic chemical raw materials, synthetic and bio-based materials, special chemical products, sealing fillers, engineering plastics, and Category I and Category II medical-device sales. It is identified as a combined company rather than an offshore company, indicating a mixed manufacturing and commercial operating model.

After-Sales capabilityThe supplier has documented and followed procedures for corrective and preventive actions and customer complaints, and technology engineers provide technical support for production and after-sales service. However, it reports no overseas agents or branches, no overseas warehouse or showroom, and zero stated countries for overseas services, limiting evidence of local international support.

R&D capabilityR&D engineers are responsible for R&D and technical support, and relevant design input, output, review, verification, and validation documents are available for audit. The supplier reports software-instrument capability using MestReNova, but no SDK is available, so the evidence supports established R&D activity rather than full software-development integration capability.

Production capacityThe supplier operates two production lines and reports defined annual capacities, including 600 tons of serum separation gel, 500 tons of tris base, 30 tons of dipotassium ethylenediaminetetraacetate, 20 tons of tripotassium EDTA, and 0.6 tons of lithium heparin. It also reports inventory capability, standardized finished-product inspection instructions, and an off-peak lead time within 15 working days; however, it lacks a valid manufacturing-capacity contract with related subcontractors.

Customization capabilityThe supplier explicitly offers design customization from samples and reports OEM services for well-known brands. Its quality-control information also states that own-brand product quality-control capability is present, although the specific designation is recorded as “DS.”